首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Dynamics of Mutator and Antibiotic-Resistant Populations in a Pharmacokinetic/Pharmacodynamic Model of Pseudomonas aeruginosa Biofilm Treatment
【2h】

Dynamics of Mutator and Antibiotic-Resistant Populations in a Pharmacokinetic/Pharmacodynamic Model of Pseudomonas aeruginosa Biofilm Treatment

机译:铜绿假单胞菌生物膜处理的药代动力学/药效学模型中的突变和抗药性种群的动力学。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Biofilm growth, antibiotic resistance, and mutator phenotypes are key components of chronic respiratory infections by Pseudomonas aeruginosa in cystic fibrosis patients. We examined the dynamics of mutator and antibiotic-resistant populations in P. aeruginosa flow-cell biofilms, using fluorescently tagged PAO1 and PAOMS (mutator [mutS] derivative) strains. Two-day-old biofilms were treated with ciprofloxacin (CIP) for 4 days (t4) at 2 μg/ml, which correlated with the mutant prevention concentration (MPC) and provided an AUC/MIC ratio of 384 that should predict therapeutic success. Biofilms were monitored by confocal laser scanning microscopy (CLSM), and the numbers of viable cells and resistant mutants (4- and 16-fold MICs) were determined. Despite optimized pharmacokinetic/pharmacodynamic (PK/PD) parameters, CIP treatment did not suppress resistance development in P. aeruginosa biofilms. One-step resistant mutants (MexCD-OprJ or MexEF-OprN overexpression) were selected for both strains, while two-step resistant mutants (additional GyrA or GyrB mutation) were readily selected only from the mutator strain. CLSM analysis of competition experiments revealed that PAOMS, even when inoculated at a 0.01 proportion, took over the whole biofilm after only 2 days of CIP treatment outnumbering PAO1 by 3 log at t4. Our results show that mutational mechanisms play a major role in biofilm antibiotic resistance and that theoretically optimized PK/PD parameters fail to suppress resistance development, suggesting that the increased antibiotic tolerance driven by the special biofilm physiology and architecture may raise the effective MPC, favoring gradual mutational resistance development, especially in mutator strains. Moreover, the amplification of mutator populations under antibiotic treatment by coselection with resistance mutations is for the first time demonstrated in situ for P. aeruginosa biofilms.
机译:生物膜生长,抗生素抗性和突变型是囊性纤维化患者铜绿假单胞菌慢性呼吸道感染的关键因素。我们使用荧光标记的PAO1和PAOMS(突变体[mutS]衍生物)菌株检查了铜绿假单胞菌流动细胞生物膜中突变体和抗生素抗性种群的动态。两天大的生物膜用环丙沙星(CIP)以2μg/ ml处理4天(t4),这与突变预防浓度(MPC)相关,并且提供的AUC / MIC比为384,可以预测治疗成功。通过共聚焦激光扫描显微镜(CLSM)监测生物膜,并确定了活细胞和抗性突变体的数量(4和16倍MIC)。尽管优化了药代动力学/药效学(PK / PD)参数,但CIP处理并未抑制铜绿假单胞菌生物膜中的耐药性发展。对于这两种菌株均选择了一步抗性突变体(MexCD-OprJ或MexEF-OprN过表达),而仅从突变体菌株中容易选择了两步抗性突变体(其他GyrA或GyrB突变)。 CLSM对竞争实验的分析表明,即使在以0.01的比例接种PAOMS的情况下,CIP处理仅2天,在t4时,PAOMS的数量就比PAO1多了3个对数。我们的结果表明,突变机制在生物膜抗药性中起主要作用,并且理论上优化的PK / PD参数不能抑制抗药性的发展,这表明由特殊生物膜生理和结构驱动的增加的抗生素耐受性可能会提高有效MPC,有利于逐步突变抗性的发展,特别是在突变株中。而且,首次通过铜绿假单胞菌生物膜原位证明了在抗生素处理下通过与抗性突变的共选择来扩增突变体群体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号